REMAIN data show MCO-010 optogenetic therapy delivered durable ~3-line vision gains in retinitis pigmentosa regardless of ...

D-150 gene therapy enters pivotal Wet-AMD/DME trials, cutting injections up to 89%. Click for this FDMT update.

View-tolerant identity recognition in humans depends on the stable identity cues provided by horizontal facial information.

Roughly one in five Americans aged 70 and older is living with both hearing loss and vision loss at the same time, according ...